DUBAI, UAE, June 9, 2021 /PRNewswire/ -- Takeda (TSE:
4502) (NYSE: TAK) has introduced the "In Their
Shoes" platform, an award-winning, immersive
simulation program to promote greater awareness and empathy for
patients with Inflammatory bowel disease (IBD), a condition to
describe Crohn's disease and ulcerative colitis, to a group of
healthcare providers in the Middle
East the first time.
The subscription-based program launched with a two-day
simulation where healthcare providers and Takeda employees learned
about the condition most effectively and profoundly: by "living
with it."
The program utilized a mobile application to guide participants
through some of the everyday struggles patients face. An "IBD kit"
of materials was used to participate in "challenges" prompted by
the app. These challenges were designed to simulate several
physical and emotional aspects of the disease. Through role-play
scenarios and interactions with actors playing nurses, and
healthcare professionals, participants gained unparalleled insight
into the impact that IBD can have across all aspects of someone's
life, including professional and personal relationships. While a
simulation can never fully replicate the pain and disruption
associated with IBD, physical discomfort and regular interruptions
incorporated into the program helped participants walk "in the
shoes" of someone with IBD.
Toby Shepard, Head of Medical
Affairs for Takeda in ICMEA, said, "The platform has been
highly successful in helping both employees and healthcare
professionals gain more knowledge about IBD by 'becoming the
patient' and experiencing what it's like to live with IBD. The
program has been developed in consultation with immersive learning
experts to help participants gain a deeper understanding of how IBD
negatively affects people in their daily lives, inspiring new
facets in their work in serving patients with IBD, whether it be in
research and development, marketing, or patient outreach. The
program seeks to support the wider healthcare community become true
advocates with a deeper emotional connection to the disease, and
ultimately improve how our healthcare partners and we support these
patients."
An evaluation study[1] conducted by the
University of Westminster, London,
UK, and published in Frontiers in Psychology demonstrated
statistically significant increases in understanding, empathy, and
connection to patients living with IBD, as well as a greater desire
to help raise public awareness and improve access to patient
support among the "In Their Shoes" participants.
As part of the program, over 1,900 participants from more than
30 countries worldwide have had the opportunity to simulate an IBD
patient's daily life via mobile app challenges, experiencing
first-hand the emotional and physical burden of living with the
disease. In early 2019, following the global success of In Their
Shoes, Takeda expanded the program's scope with the launch of a new
version simulating a patient's life with Crohn's disease living
with a complex perianal fistula.
1. Halton C, Cartwright T. Walking in a
Patient's Shoes: An Evaluation Study of Immersive Learning Using a
Digital Training Intervention. Front Psychol [Internet]. Available
from:
https://www.frontiersin.org/articles/10.3389/fpsyg.2018.02124/full.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) (NYSE: TAK) is
a global, values-based, R&D-driven biopharmaceutical leader
headquartered in Japan, committed
to bringing Better Health and a Brighter Future to patients by
translating science into highly-innovative medicines. Takeda
focuses its R&D efforts on four therapeutic
areas: Oncology, Rare Diseases, Neuroscience, and
Gastroenterology (GI). We also make targeted R&D investments in
Plasma-Derived Therapies and Vaccines. We are focusing on
developing highly innovative medicines that contribute to making a
difference in people's lives by advancing the frontier of new
treatment options and leveraging our enhanced collaborative R&D
engine and capabilities to create a robust, modality-diverse
pipeline. Our employees are committed to improving quality of life
for patients and to working with our partners in health care in
approximately 80 countries. For more information, visit
https://www.takeda.com.
For more information:
mohammed.alnasseri@fleishman.com
M: +971 507694646
View original
content:http://www.prnewswire.com/news-releases/takeda-introduces-the-in-their-shoes-experience-to-the-middle-east-in-support-of-the-ibd-patient-community-301309252.html
SOURCE Takeda Pharmaceuticals